29 results on '"Greene, Julia M."'
Search Results
2. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39’: An analysis of safety and immune response
3. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors
4. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2
5. 522 UNDER-UTILIZATION OF NEOADJUVANT THERAPY FOR ELDERLY PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER
6. Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
7. Subgroup Analysis of the Interim Results of a Prospective, Randomized, Double Blinded, Placebo Controlled, Phase IIb Trial of the Autologous TLPLDC Vaccine in Stage III/IV (Resected) Melanoma Patients to Prevent Recurrence
8. Abstract CT150: Initial analysis of open-label administration of autologous tumor lysate (TL) + dendritic cells (DC) vaccine (TLPLDC) in melanoma patients who recurred during a phase IIb adjuvant vaccine trial
9. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine
10. A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
11. Immunologic efficacy of E39 & E39' vaccination in a phase I/IIa trial in ovarian and endometrial cancer patients.
12. Final Analysis of a Randomized Phase 1b Trial to Assess Sequencing of the E39 and E39' Vaccines to Optimize Long-Term Antitumor Immunity in Folate Binding Protein (FBP) Expressing Tumors
13. A novel cancer vaccine platform utilizing autologous tumor lysate loaded into capped yeast cell wall particles.
14. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
15. Abstract B007: Improved disease-free survival in endometrial and ovarian cancer patients with low folate binding protein expression after treatment with the E39 peptide vaccine in a Phase I/IIa trial
16. Phase Ib Trial Comparing Different Doses and Schedules of a Folate-Binding Protein-Derived Peptide Vaccine, E39, and its Attenuated Version, E39’, to Induce Long-Term Folate-Binding Protein-Specific Immunity in Disease-Free Cancer Patients
17. Abstract CT073: Comparing an attenuated booster (E39’) vs E39 booster to potentiate the clinical benefit of the folate binding protein (FBP)-derived vaccine (E39 + GM-CSF) in a phase I/IIa trial to prevent recurrence in endometrial (EC) and ovarian cancer (OC) patients
18. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
19. The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence.
20. Abstract A044: Initial phase I/IIa trial results of an autologous tumor lysate + yeast cell wall particles + dendritic cells vaccine (TLPLDC) in patients with solid tumors
21. Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
22. Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients
23. Abstract CT209: Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine
24. Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence.
25. Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
26. Abstract OT3-1-09: Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence
27. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
28. Fragmentation Injury to the Innominate Artery in a Three-Year-Old Child
29. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.